English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In recent years, with the development of immunotherapy, immune checkpoint inhibitors (ICIs) have gradually changed the treatment pattern of solid malignant tumors. As more ICIs are approved for clinical use, more patients with tumors may obtain a better prognosis. Commonly used ICIs include programmed cell death protein-1 (PD1) inhibitors (such as nivolumab and pembrolizumab), programmed death-ligand 1 (PD-L1) inhibitors (such as atezolizumab, durvalumab, and avelumab), and cytotoxic Original Article

translational cancer research

The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis